CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML
Authors
Yoana Arroyo-Berdugo
Michael Austin
+15 more
Yolanda Calle
Armando Cevenini
Luca Cozzuto
Pedro Cutillas
Antonella Di Mambro
Gabriella Esposito
Maria T. Esposito
Tiziana Fioretti
John Gribben
Claire Lucas
Bela Patel
Julia Ponomarenko
Vinothini Rajeeve
Michael Randles
Owen Williams
Publication date
1 January 2023
Publisher
Springer Nature
Doi
Cite
Abstract
© 2023, The Author(s). The version of record of this article, first published in [Oncogene], is available online at Publisher’s website: http://dx.doi.org/10.1038/s41388-023-02840-1KMT2A-rearranged (KMT2A-R) is an aggressive and chemo-refractory acute leukemia which mostly affects children. Transcriptomics-based characterization and chemical interrogation identified kinases as key drivers of survival and drug resistance in KMT2A-R leukemia. In contrast, the contribution and regulation of phosphatases is unknown. In this study we uncover the essential role and underlying mechanisms of SET, the endogenous inhibitor of Ser/Thr phosphatase PP2A, in KMT2A-R-leukemia. Investigation of SET expression in acute myeloid leukemia (AML) samples demonstrated that SET is overexpressed, and elevated expression of SET is correlated with poor prognosis and with the expression of MEIS and HOXA genes in AML patients. Silencing SET specifically abolished the clonogenic ability of KMT2A-R leukemic cells and the transcription of KMT2A targets genes HOXA9 and HOXA10. Subsequent mechanistic investigations showed that SET interacts with both KMT2A wild type and fusion proteins, and it is recruited to the HOXA10 promoter. Pharmacological inhibition of SET by FTY720 disrupted SET-PP2A interaction leading to cell cycle arrest and increased sensitivity to chemotherapy in KMT2A-R-leukemic models. Phospho-proteomic analyses revealed that FTY720 reduced the activity of kinases regulated by PP2A, including ERK1, GSK3β, AURB and PLK1 and led to suppression of MYC, supporting the hypothesis of a feedback loop among PP2A, AURB, PLK1, MYC, and SET. Our findings illustrate that SET is a novel player in KMT2A-R leukemia and they provide evidence that SET antagonism could serve as a novel strategy to treat this aggressive leukemia. [Abstract copyright: © 2023. The Author(s).
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Supporting member
Queen Mary Research Online
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:qmro.qmul.ac.uk:123456789/...
Last time updated on 04/12/2023
ChesterRep
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:chesterrep.openrepository....
Last time updated on 13/11/2023
UPF Digital Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:repositori.upf.edu:10230/5...
Last time updated on 15/05/2024
University of Liverpool Repository
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:livrepository.liverpool.ac...
Last time updated on 12/02/2024